Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.37
-0.03 (-0.15%)
At close: Aug 10, 2026, 4:00 PM EDT
20.30
-0.07 (-0.34%)
After-hours: Aug 10, 2026, 7:34 PM EDT
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Syndax Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $38.27. The average 1-year stock price forecast is 87.87% higher than the current stock price, while the lowest is $26 (+27.64%) and the highest is $57 (+179.82%).
Price Target: $38.27 (+87.87%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 10 | 10 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $26 | Buy | Maintains | $26 | +27.64% | Aug 5, 2026 |
| Citi | Citi | Buy Maintains $57 | Buy | Maintains | $57 | +179.82% | Aug 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $40 → $38 | Buy | Reiterates | $40 → $38 | +86.55% | Aug 5, 2026 |
| Barclays | Barclays | Buy Maintains $37 | Buy | Maintains | $37 | +81.64% | Aug 5, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 5, 2026 |
Financial Forecast
Revenue This Year
317.90M
from 172.35M
Increased by 84.45%
Revenue Next Year
480.82M
from 317.90M
Increased by 51.25%
EPS This Year
-1.95
from -3.29
EPS Next Year
-0.49
from -1.95
EPS and Forward PE are based on non-GAAP adjusted numbers.